Protocol Ledger

NCT05111574 · Phase II · ACTIVE NOT RECRUITING

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Interventional Phase II clinical trial protocol NCT05111574 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-11 Enrollment: 101 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05111574
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)101 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05111574
Protocol FieldVerified Registry Value
NCT IdentifierNCT05111574
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment101 participants (ESTIMATED)
Registered Start Date2022-08-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI